Figitumumab
Figitumumab
Figitumumab (pronounced: fi-gi-tu-mu-mab) is a type of monoclonal antibody that was under development for the treatment of various types of cancer. It was developed by Pfizer, but its development was discontinued in 2011 due to lack of efficacy in clinical trials.
Etymology
The name "Figitumumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the "tumu-" infix suggests its use in tumor-related conditions. The origin of "Figi-" is not known.
Mechanism of Action
Figitumumab works by binding to the Insulin-like growth factor 1 receptor (IGF-1R), thereby inhibiting the growth and proliferation of cancer cells. IGF-1R is a type of tyrosine kinase receptor that is often overexpressed in various types of cancer.
Clinical Trials
Figitumumab was tested in several clinical trials for the treatment of non-small cell lung cancer (NSCLC), prostate cancer, and sarcoma. However, the trials did not show significant improvement in patient outcomes, leading to the discontinuation of its development.
Related Terms
- Monoclonal antibody
- Insulin-like growth factor 1 receptor
- Tyrosine kinase receptor
- Non-small cell lung cancer
- Prostate cancer
- Sarcoma
External links
- Medical encyclopedia article on Figitumumab
- Wikipedia's article - Figitumumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski